Andy Serkis to Receive IBC’s Highest Award
30.7.2019 18:02:00 EEST | Business Wire | Press release
The IBC2019 International Honour for Excellence will go to Andy Serkis, the director, producer and actor who is today best known for his performance capture roles. These include Gollum, Supreme Leader Snoke, King Kong and Caesar in the Planet of the Apes series. Serkis will accept the award at the climax of the IBC2019 Awards Ceremony, on Sunday night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005738/en/
Andy Serkis (Photo: Business Wire)
“IBC is where the technology, the craft and the business of the media industry come together,” said Michael Crimp, CEO of IBC. “The International Honour for Excellence has a long history of rewarding those who have transformed our creative vision. Andy Serkis has achieved this by bringing extraordinary humanity to computer-generated characters.”
Serkis was born in England in 1964 and wanted to be an artist before becoming an actor, working in the theatre and on television. Today he is also a producer and director, with his London-based company Imaginarium Studios producing last year’s Mowgli, Legend of the Jungle, a new interpretation of Kipling’s originals adapted by Serkis, which also featured him co-starring as Baloo the bear alongside Christian Bale’s Bagheera.
His greatest achievement, though, is in making the shift from mere motion capture for CGI towards a combination of technology and the interpretive skill of the actor to create the fidelity of the performance in every detail. This is what gives the performance genuine humanity: his performance as Caesar in the three Planet of the Apes films won him an acting nomination from the Broadcast Film Critics Association.
For bringing together the highest performance standards with the latest in image recognition and CGI technology, the IBC2019 International Honour for Excellence will be presented to Andy Serkis.
“I feel incredibly honoured to have been chosen as the recipient of this year’s prestigious IBC award,” said Andy Serkis. “In turn, I must share this appreciation with the phenomenal legions of creative artists, visionaries and pioneers with whom I’ve been lucky enough to dance with on this journey of next generation storytelling.”
The IBC2019 Awards Ceremony is free to all IBC visitors. It takes place on Sunday evening 15 September at 18.30 in the RAI Auditorium, and will also see the presentation of two new awards this year, honouring achievements in social responsibility and a Young Pioneer, alongside the IBC Innovation Awards.
Earlier on Sunday Andy Serkis will feature in an IBC2019 Conference Convention Keynote , in conversation with Hollywood journalist Carolyn Giardina. They will review his career, the state of the art in motion capture, and discuss where he sees the future of technology in film and television. The Convention Keynote is at 12.30 in the Forum, and is free to attend.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005738/en/
Contact information
Aimee Moore
amoore@ibc.org
+44 (0) 20 7832 4104
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
